Table 2.
In vitro anticancer activity of the synthesized compounds 7(a–l).
| Entry | GI50 µM | ||||
|---|---|---|---|---|---|
| MCF-7 | HeLa | SKMEL-2 | HL-60 | MCF-10A | |
| 7a | 22.9 | 32.8 | 21.9 | 21.7 | >100 |
| 7b | 28.7 | 39.0 | 22.9 | 28.2 | 86.1 |
| 7c | 32.4 | 41.1 | 27.5 | 33.3 | ND |
| 7d | 36.7 | 52.4 | 34.0 | 40.2 | ND |
| 7e | 35.2 | 46.8 | 28.1 | 39.6 | ND |
| 7f | 38.4 | 49.2 | 30.0 | 37.5 | ND |
| 7g | 41.0 | 66.1 | 46.4 | 42.4 | ND |
| 7h | 46.2 | 71.7 | 49.1 | 48.2 | ND |
| 7i | 49.0 | 78.0 | 52.6 | 45.8 | ND |
| 7j | 51.4 | 78.8 | 55.7 | 49.9 | ND |
| 7k | 11.7 | 23.8 | 19.6 | 35.5 | > 100 |
| 7l | 19.0 | 28.8 | 22.0 | 29.9 | > 100 |
| ADR | < 10 | < 10 | < 10 | < 10 | ND |
ADR Adriamycin standard drug used.GI50 is the concentration exhibiting 50% inhibition of the growth, as compared to the growth of control.MCF-7 human breast cancer cell line, HeLa human cervical cancer cell line, SKMEL-2 human melanoma cancer cell line, HL-60 human leukemia cancer cell line, MCF-10A normal breast epithelial cell lines and ND = Not determined.